Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Genome Sciences, University of Washington, Seattle, Washington, USA.
J Infect Dis. 2021 Feb 3;223(2):197-205. doi: 10.1093/infdis/jiaa618.
Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
大多数感染严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的个体都会产生针对病毒刺突蛋白的中和抗体。在这项研究中,我们通过检查从具有无症状、轻度或中度-重度疾病的 32 名康复个体中大约在症状出现后 30-152 天采集的前瞻性队列的纵向样本,定量研究了这些抗体在 SARS-CoV-2 感染后数月内的变化。中和抗体滴度从症状出现后 1 至 4 个月平均下降约 4 倍。这种中和抗体滴度的下降伴随着能够结合病毒刺突蛋白或其受体结合域的总抗体的下降。重要的是,我们的数据与对病毒感染的预期早期免疫反应一致,其中抗体水平最初出现峰值,然后下降到较低的平台。需要对长寿 B 细胞和更长时间范围内的抗体滴度进行更多研究,以确定对 SARS-CoV-2 的免疫持久性。